Hutchmed (Nasdaq: HCM) says that the first commercial sale in China of Orpathys (savolitinib), the Chinese firm's oral, potent, and highly selective small molecule inhibitor of MET, a receptor tyrosine kinase, occurred on July 12, 2021.
This follows less than three weeks after the June 22, 2021 approval of Orpathys in China for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with MET exon 14 skipping alterations who have progressed following prior systemic therapy or are unable to receive chemotherapy
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze